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Abstract
Quality of life is a major goal in the context of preventive and therapeutic cardiology. It is important,
both as an outcome measure in clinical trials of congestive heart failure (CHF) and as a
consideration in individual physicians' therapeutic decisions. In this article, quality of life concepts
are reviewed, methods of measurement are explored and clinically significant changes on prognosis
are discussed. There is a need for more research which is based on carefully selected measures of
quality of life chosen as being of particular importance to patients and to the hypotheses being
tested.
1. Introduction
Congestive heart failure (CHF) is a major health problem,
with an increasing incidence and a gloomy prognosis, that
is often accompanied by restricted physical activity and
severe complaints in several areas of quality of life [1].
Despite its high prevalence, there have been few studies of
the impact of CHF on quality of life, especially in the com-
munity and in the elderly patient [2], suggesting the need
of epidemiology of quality of life as a part of epidemiol-
ogy of "positive mental health" strictly closed with mental
health. According to Stott, to the population of ageing,
elderly heart failure patients who have multiple co-mor-
bidities, quality of life, disability and cognitive impair-
ment are the elements which matter to measure [3].
Since 1948, when the World Health Organization defined
health as being not only the absence of disease and infir-
mity but also the presence of physical, mental and social
well-being, quality of life issues have become steadily
more important in health care practice and research [4].
2. Definition of quality of life
The concept of quality of life is not yet defined in a uni-
form way, lacks clarity and even creates confusion. It
seems that in medicine, the term has become a band-
wagon concept for all those human needs which are often
neglected in a health care field increasingly dominated by
technology. It is justifiable to say that it is a term describ-
ing a field of interest rather than a single variable [5].
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Health status, functional status and quality of life are three
concepts often used interchangeably to refer to the same
domain of "health". Guyatt used the term "health related
quality of life" (HRQL) because many widely valued
aspects of life are not generally considered as "health-
related" include income, freedom and quality of the envi-
ronment [6].
As a rule, "quality of life" is used in medicine for charac-
terising an individual patient's quality of life from his or
her own subjective perspective [5]. HRQL, to Schipper
and associates, can be defined as "... the functional effect
of an illness and its consequent therapy upon a patient, as
perceived by the patient" [6]. It has been found logical to
distinguish sharply between diseases, which explain ill-
ness behaviour, and other states of health, which do not
have an explanatory element but might be seen as a con-
sequence of having one or more illnesses [7]. So, HRQL
measures the illness experience as opposed to the disease
[6], it defines the patient reality, his or her point of view
as opposed to the reality defined by professional medical
knowledge [8].
3. Measuring the quality of life
Measures of the quality of life in chronically ill patients
provide an important source of medical information in
addition to laboratory or diagnostic tests [8] and are
becoming increasingly relevant to controlled clinical trials
[6]. One goal of the measurement of quality of life is to
have objective evaluations of how and how much the dis-
ease influences patients'life and how patients cope with it.
These evaluations may be useful as a baseline and out-
come measures and should provide framework to deter-
mine the impact of any change on patients'quality of life
[9].
In the first phase of quality of life research in the 1970s
and early 1980s, already available psychological well-
being scales were used or new ones were specifically devel-
oped for this purpose. Examples are the "Affect Balance
Scale" (ABS) by Bradburn (1969); the "Quality of Well-
Being Scale" (QWBS) by Kaplan et al (1976) and the "Psy-
chological General Well-Being Index" (PGWB) by Dupuy
(1984). This particular development has connections to
the "happiness research" tradition within psychology,
where well-being is discussed not only in terms of absence
of negative factors (such as depressed mood), but as a pos-
itive concept.
From the 1980s onwards, in addition to the assessment of
well-being and satisfaction, instruments for assessing
functioning in daily life were developed. This develop-
ment is subsumed under the term "health status research".
Well- known examples of "health status research" instru-
ments are the Sickness Impact Profile (SIP) by Bergner et
al (1981); the Nottingham Health Profile (NHP) by Hunt
and McEwen (1980) and the Rand SF-36 Health Status
Profile by Ware and Sherbourne (1992). Although these
instruments do not use the term "quality of life", studies
employing them are today generally regarded as belong-
ing to health- related quality of life research. Later – in
contrast to these "generic instruments" – disease specific
quality of life instruments were developed [5].
General (or generic) measures attempt to provide a sum-
mary of quality of life and they can be standardized and
applied widely to those with different types of illness to
enable comparisons [10], but they lack the range, sensitiv-
ity and flexibility to deal with the special problems of par-
ticular illness.
Specific measures focus on problems associated with indi-
vidual disease states, patients groups or areas of function
[6]. Specific instruments tend to be more responsive to
changes and more sensitive in discriminating the range of
impairment because of their focus on the most relevant
aspects of quality of life for the problems assessed. Never-
theless, using a disease specific quality of life instrument
alone can miss important aspects of the impact of a dis-
ease in quality of life [10-12]. There is a need for more
research, which is based on carefully selected specific
measures of quality of life chosen as being of particular
importance to patients and to the hypotheses being tested
[13]. Some examples of specific instruments to measure
quality of life in heart failure patients are: the Chronic
Heart Failure Questionnaire; the Minnesota Living with
Heart Failure Questionnaire; the Yale Scale; the Quality of
Life Questionnaire in Severe Heart Failure and the Kansas
City Cardiomyopathy Questionnaire, etc.
As there are benefits with each type of instrument, it is rec-
ommended often that both (generic and specific instru-
ments) should be used [10,14]. However, a critical
analysis of the properties of the growing range of generic
and disease specific measures is necessary in order to
guide and direct researchers and clinicians towards the
most appropriate measures in terms of reliability, validity
and sensitivity to change [10].
Instruments used in measuring quality of life must be
valid (if it is really measuring what is supposed to meas-
ure); reliable (if it gives the same measurement after
repeated administration in stable patients); sensitive (if it
is able to reflect clinically meaningful differences in qual-
ity of life across the broad spectrum of the clinical condi-
tions) and responsive (if it detects changes when the
patients' conditions change) [11].Clinical Practice and Epidemiology in Mental Health 2005, 1:19 http://www.cpementalhealth.com/content/1/1/19
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4. Domains of quality of life
Domains of quality of life refer to areas of behaviour that
are measured.
The subjective domains of quality of life are: physical
functioning (the capacity to perform physical tasks); occu-
pational functioning (quality of life should focus on the
ability to perform multiple essential roles and not just on
return to work); perceptions about health status (health
perceptions are personal beliefs and evaluations of gen-
eral health status, they are the result of integration of
information and feelings about health and health limita-
tions from the self, the medical system, the family and the
society); psychological functioning and social function-
ing. Siegrist and Junge (see Swenson and Clinch) [11]
defined social health as the dimension of an individual's
well-being that concerns how the individual gets along
with others, how other people react to him or her, and
how the person interacts with social institutions and
norms.
In the domain of objectivity we can include: health status
(measured by laboratory or diagnostic tests); psycopha-
tology (CID-10/DSM-IV-TR); socio-economic status and
social support (number and quality of the contacts).
Thompson et al (see Majani et al, 1999) stated that "objec-
tive measures of quality of life often bear little relation-
ship to life satisfaction, whereas subjective indicators are
often found to correlate highly with a global sense of well-
being, as well as being more meaningful and sensitive
barometers of quality of life". Accordingly, patients'sub-
jective satisfaction should always be included in routine
assessment and clinical interventions; they are a useful
source of information on patient distress and psychologi-
cal resources [15].
5. Assessing quality of life among people with 
CHF
Advanced CHF is the final outcome of many cardiovascu-
lar disorders. Despite recent improvement in survival
related to newer therapies, CHF remains a condition with
such a generally poor prognosis that the critical therapeu-
tic advantages are more likely to be those that maintain
and stabilize the patient's limited functional abilities and,
by ameliorating symptoms, improve the comfort of the
patient for the remaining duration of life. Prolongation of
survival without these benefits may be viewed as a less
important objective [16,17]. According to Coats et al opti-
mally treated patients are often left with unrelieved symp-
toms and have a correspondingly low quality of life [18].
The development in the recent years of standardised
measures of quality of life in CHF reflects the growing per-
ception of the importance of these outcomes in patients
[19]. The achievement of quality of life measures in CHF
can be summarised as follows: general profiles of popula-
tions with CHF in terms of quality of life have been devel-
oped; the validity of the measuring instruments has been
tested and correlated with clinical outcome; the need to
include quality of life studies as outcome measures in clin-
ical trials such as SOLVD has been recognised [9].
5.1 Quality of life in patients with CHF: comparison with 
other chronic diseases
Juenger et al compared the quality of life of patients with
CHF with a previously characterised general population
and with those with other chronic diseases. Patients'self
assessment of quality of life was measured by the SF-36.
The authors concluded that the total CHF sample was
characterised by significantly reduced scores in all aspects
of quality of life compared with a healthy reference group.
Patients with CHF showed the same pattern of reduced
quality of life as patients on chronic haemodialysis, thus
it could be argued that all chronic disease conditions have
a similar impact on quality of life, however patients with
chronic hepatitis C had higher scores in physical function-
ing, role functioning, physical and general health than the
CHF population. In comparison with patients with major
depression from the Medical Outcome Study, the total
CHF sample was characterised by significantly worse
physical health (as expected) and better mental health.
However, patients with more advanced CHF (NYHA III)
had similar scores to patients with major depression on
the mental health scales in addition to their already dra-
matically reduced physical health. These data are in
accord with the findings of some recent studies showing
that a large proportion of patients with CHF suffer from
depression. [20]
5.2 Quality of life, medical treatment and clinical outcome
As has occurred with other chronic medical problems for
which several therapies have produced comparable sur-
vival benefit, additional attributes or consequences of
these therapies are then considered to warrant evaluation,
among them the effects on quality of life, as a means to
select an optimal drug regimen. The emergence of quality
of life as an outcome measure in clinical trials of cardio-
vascular, as well as other therapies appears associated with
additional changes in contemporary medical care [16].
Wenger suggested that quality of life measurements are
particularly useful with respect to investigating treatment
of cardiovascular disease in three instances: 1) when there
is little likelihood of one treatment showing a major
improvement in survival over another in a clinical trial.
Quality of life measurement in such a trial might point
toward the choice of the therapy showing the greatest ben-
efit for improving it; 2) when a treatment is effective in
reducing mortality, but has toxic or unacceptable side
effects. Quality of life measurement in this case may helpClinical Practice and Epidemiology in Mental Health 2005, 1:19 http://www.cpementalhealth.com/content/1/1/19
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physicians and their patients weight the benefits and risks
of such a treatment; 3) when patients are asymptomatic or
have mild symptoms, the morbidity and mortality rates
are low, and the therapy is long term. Quality of life meas-
urement would ensure that quality of life is not dimin-
ished unacceptably and there is reasonable chance of
compliance with therapy [11]. This is one of the areas
where most of medical research is currently centred on
and it is strongly supported by the pharmaceutical indus-
try [21].
According to Konstam et al (1996) attention has recently
been directed to quality of life in the treatment of CHF
patients; however, few systematic studies actually depict
the relation between quality of life and clinical outcome.
These authors found that the baseline assessment of qual-
ity of life independently predicted mortality and CHF
related hospitalisations in symptomatic and asympto-
matic patients randomised to enalapril or placebo treat-
ment (Studies of Left Ventricular Dysfunction trial-
SOLVD – patients with an ejection fraction < 0.35 were
followed for a mean of 36.5 months). The domains of
activities of daily living (ADL) and general health pre-
dicted mortality and CHF related hospitalisations in both
univariate and multivariate analysis. Quality of life
indexes provided additional predictive values with respect
to both mortality and CHF related hospitalisations, above
and beyond the predictive power of variables such as ejec-
tion fraction, age, treatment (enalapril vs placebo) and the
NYHA classification. These findings support the argument
that a patient functional and psychological status repre-
sent independent risk factors for morbidity and mortality
and warrant the need for further investigations regarding
the mechanisms by which self-rated activity level predicts
mortality and CHF related hospitalisations (this might
include a closer look on psychological mechanisms and
the pathophysiology underlying activity level). This study
also supports the need to include quality of life in the
evaluation and course of treatment of CHF [22].
Jenkinson et al (see O'Keefe et al, 1998) noted that the SF-
36 and the Darmouth CCOP, two generic measures of
quality of life were not responsive to self-reported
improvements in global health in a study of elderly CHF
patients starting treatment with ACE inhibitor. O'Keefe et
al used the Chronic Heart Failure Questionnaire (CHQ),
a CHF specific quality of life measure, in a similar popu-
lation and found different results. It maybe possible that
ACE inhibitors, despite their beneficial effect on mortal-
ity, do not lead to major improvement in quality of life;
however, the better responsiveness of the CHQ may sim-
ply reflect that it is an instrument specifically designed for
use in CHF [19].
Many studies have been performed in patients with CHF
of various aetiologies and the beneficial effect of long-
term beta blockade, has been confirmed [23]. According
to these authors, numerous studies have shown that beta
blockade when given for more than two months, elicit sig-
nificant improvement in functional class, exercise capac-
ity, cardiac function, quality of life and/or morbidity.
Several large studies have also reported benefits on mor-
tality and morbidity. Randomised placebo controlled tri-
als with β1  blockade in patients with CHF reporting
quality of life or NYHA functional class have yielded
inconsistent results. While studies with β1 selective agents
have shown improvement in quality of life or NYHA class,
others with non-selective agents have shown a less clear
picture and still others have failed to show significant
improvement in quality of life or NYHA class [19].
5.3 Quality of life and somatic variables
According to Juenger et al few studies have investigated
the relation between quality of life and clinical variables
(reflecting the severity of disease) in CHF and most of
these studies achieved inconclusive results. These authors
studied the relation between quality of life (assessed by a
generic quality of life measure:SF-36) and somatic indices
(that included the assessment of New York Heart Associa-
tion – NYHA, functional class, left ventricular ejection
fraction, peak oxygen uptake and the distance covered
during a standardised six minute walk test). They con-
cluded that quality of life decreases as NYHA functional
class worsens. The peak oxygen uptake and the six minute
walk test also showed some relation to the quality of life
(patients with a more severe impairment of functional
capacity had, in general, significantly lower SF-36 values).
In contrast, left ventricular ejection fraction showed no
clear association with quality of life. These findings may
also explain why beta blockade treatment in CHF has no
consistent effect on the quality of life, despite a pro-
nounced improvement in left ventricular ejection frac-
tion, whereas the increase in peak oxygen uptake achieved
by exercise training is associated with an improvement in
quality of life [20].
5.4 Social support as a measure of clinical outcome
Numerous studies of cardiac patients (coronary heart dis-
ease patients) have reported that lack of social support
and social isolation are associated with increased risk of
mortality, but the study undertaken by Murberg et al
(2000) was the first detecting an effect of social isolation
(a patient's perception that he or she is no longer able to
maintain the same degree of social contacts and activities
with family, other relatives and friends as previously) on
mortality among CHF patients. Another finding concerns
the relationship between lack of intimate network support
and mortality: for the CHF patients, most of them elderly,
lack of social support from a spouse seems to be a moreClinical Practice and Epidemiology in Mental Health 2005, 1:19 http://www.cpementalhealth.com/content/1/1/19
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critical factor of fatal outcome than lack of social support
from primary and secondary network. The authors
pointed two possible explanations for that: poor network
support might be associated with poor compliance to
physical and medical regimens and that poor compliance
may lead, in turn, to a dismal outcome; it could be also
that the association between social isolation and mortal-
ity is a reflection of some underlying factors such as sub-
jective health or hopelessness, which have been reported
in several studies to be strong predictors of mortality inde-
pendently of depression [24].
5.5 Socio-economic status and hospital readmission
Philbin et al noted that the socio-economic status was an
independent risk factor for CHF. The principal findings of
their study suggest that differences in age, sex, race, insur-
ance, coexistent illness and location of care do not fully
explain the higher frequency of readmission among low-
income patients, but rather imply that other causes may
exist. The authors discuss possible causes to these find-
ings: low-income patients may have diminished access to
such care (rural hospitals may be less likely to offer com-
prehensive programs for management of CHF); financial
constraints and educational limitations, more common
among low-income persons, could compromise compli-
ance with treatment recommendations and lead to higher
rate of hospitalisations; substance abuse and cigarette
smoking, more common among minorities with heart
failure could also play an important role [25].
5.6 Quality of life and depression
Investigation of the links between emotion and the devel-
opment and prognosis of CHF have been the focus of
much psychosomatic research of patients with cardiac dis-
ease over the last years. Depression is the most explored
psychosocial factor in patients with CHF. Anxiety, how-
ever, was far less investigated. From the available data it
seems that anxiety is not affecting heart failure patients to
a greater extent. However, it has been shown that emo-
tional distress prior to hospitalization was twice as com-
mon in patients with CHF when compared to other
patients [26].
With respect to depression, recent studies have shown that
the presence of depressive symptoms below the severity
threshold for a depressive disorder is associated with ele-
vated cardiac mortality. However, the nature of the rela-
tionship between depressive symptoms and elevated risk
of cardiac mortality is unclear.
Longitudinal studies of quality of life in people at risk for
heart disease may help clarify the nature of interactions
between affective states, physical and social function,
health perceptions and cardiac events [11].
Rumsfeld et al (2003) conducted a multicenter prospec-
tive cohort study of 460 outpatients with CHF with the
purpose of assess whether depressive symptoms are inde-
pendently associated with changes in CHF specific health
status. The patients completed a baseline Medical Out-
comes Study Depression Questionnaire and both a base-
line and follow-up (6 ± 2 weeks) Kansas City
Cardiomyopathy Questionnaire (KCCQ) were analyzed.
Approximately 30% of the patients had significant depres-
sive symptoms at baseline. Depressed patients had mark-
edly lower KCCQ summary scores. After adjustment for
potencial confounders, depressed patients were at risk for
significant worsening of their CHF symptoms, physical
and social function, and quality of life. The authors con-
cluded that depressive symptoms were a strongest predic-
tor of short-term worsening of CHF-specific health status
[27]. Also Gottlieb et al (2004) studied the prevalence of
depression in an outpatient heart failure population and
its relationship to quality of life. A total of 155 patients
were evaluated with the Medical Outcomes Study-Depres-
sion questionnaire, the Minnesota Living with Heart Fail-
ure questionnaire and the Beck Depression Inventory
(BDI). A total of 48% of the patients scored as depressed
and these scored significantly worse than non-depressed
patients on all components of both the questionnaires
measuring quality of life. In this study depression was
observed more commonly among younger than older
patients. This study is consistent with the notion that
depressed CHF patients may perceive their quality of life
to be lower and to underestimate their functional status.
The higher incidence of depression in the young suggests
that depression is due to a larger disparity between the
perception of functional status and the expectation.
Patients'perceptions of their health status are more impor-
tant than their absolute physiological impairment in
determining both degree of depression and quality of life.
This may lead physicians caring for depressed CHF
patients to classify them as more severely compromised
and rate their NYHA functional class higher [28].
Havraneck EP et al (2004) tried to identify the sociodemo-
graphic and clinical factors associated with the onset of
depressive symptoms in outpatients with CHF. The
patients were evaluated at baseline and one year later with
a Medical Outcomes Study-Depression questionnaire, a
Kansas City Cardiomyopathy Questionnaire (KCCQ) and
a full clinical evaluation including patients social and eco-
nomic status. Of 245 patients without depressive symp-
toms at baseline, 52 (21,2%) developed depressive
symptoms one year later. In multivariable analysis, living
alone, alcohol abuse, perception of medical care as being
a substancial economic burden, and health status as meas-
ured by the KCCQ were independent predictors of devel-
oping depressive symptoms. The results of this study
support the use of measures of quality of life in evaluatingClinical Practice and Epidemiology in Mental Health 2005, 1:19 http://www.cpementalhealth.com/content/1/1/19
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patients with CHF. Health status measures have been
shown to predict mortality and cardiac events in cardio-
vascular populations, including CHF. The KCCQ scores
have previously been associated with subsequent mortal-
ity and hospitalization in patients with CHF. In this study,
KCCQ score was one of four independent risk factors for
the development of depression among outpatients with
CHF, so, it may aid in identification of patients at risk for
a wide range of adverse outcomes. Future studies are war-
ranted to evaluate whether health status-guided manage-
ment of patients with CHF can improve outcomes [29].
The finding of an association between psychosocial fac-
tors and morbidity and mortality in patients with CHF
underscore the importance of beginning to target these
factors and not just tradicional medical factors for inter-
vention. The failure of medical therapy to produce
marked improvement in quality of life is sobering and
highlights the need to examine other methods of improv-
ing psychosocial outcomes in patients with CHF.
Although few investigators have examined the effect of
interventions on psychosocial variables, there is evidence
that nonpharmacologic interventions may be quite effec-
tive in improving psychosocial outcomes. For example,
exercise, CHF disease management programs, stress man-
agement and cognitive therapy, biofeedback relaxation
[30], well-being therapy [31] have all been shown to
improve quality of life or depression. Interventions aimed
at improving social support have been successful in other
populations and deserve attention in patients with CHF.
In general, nonpharmacological intervention appears to
be a fruitful area for future research and practice.
5.7 Quality of life and reabilitations programs
Quality of life is a major goal in the context of preventive
and therapeutic cardiology. Randomized controlled trials
have demonstrated that comprehensive cardiac rehabilita-
tion can enhance quality of life by decreasing specific
symptoms, augmenting functional capacity and enhanc-
ing mood state [32,33].
Fonarow et al (1997) pointed out that a comprehensive
heart failure management (which included adjustments
in medical therapy and intensive patient education) led to
improved functional status and an 85% decrease in the
hospital admission rate for transplant candidates dis-
charged after evaluation. The potential to reduce both
symptoms and costs suggests that referral to a heart failure
program may be appropriate not only for potential heart
transplantation, but also for medical management of per-
sistent functional class III and IV heart failure [34].
There is little information concerning the impact of thera-
peutic exercise programs on quality of life of patients with
CHF, but benefit is likely from an earlier return to work (a
gain in physical function) and an increase in aerobic
power (physical function, physical role, fatigue and vital-
ity) [35].
Wielenga et al (1997) studied the effect of exercise training
on quality of life and exercise capacity in 35 patients with
mild to moderate chronic heart failure. Three measures
were used to evaluate quality of life: the Heart Patients
Psychological Questionnaire; the Sickness Impact Profile
and the Self- Assessment of General Well-Being. With this
study the authors confirmed that exercise training can be
performed safely by patients with mild to moderate CHF
and that after 12 weeks of physical training an increase in
exercise performance was observed. These results support
the concept that exercise training is an important modal-
ity to increase quality of life in CHF [1] and may improve
the psychological outlook and self confidence of patients
[9]. Furthermore, the observation that the increase in
training level is not reflected as an increase in peak VO2,
suggests that the increase in exercise test duration is
related to a psychological improvement, rather than to a
physical improvement. This is in accordance with the
well-known belief that exercise duration is a motivation-
dependent test parameter [1], often explains why patients
are able to accomplish many more of the activities of daily
living than exercise testing suggests is possible. However,
there are no standard ways to assess motivation, which is
influenced by many factors such as emotional state, per-
sonality, financial gain or loss, and interpersonal relation-
ships [11].
6 Conclusion
In the first documented medical journal when the term
"quality of life" was used (Annals of Internal Medicine of
1966), the author (J.R.Elkinton) quotes Francis Bacon's
view that "the office of medicine is but to tune this curious harp
of man's body and reduce it to harmony". This is a most
remarkable definition of quality of life because it stresses
not only "well-being" and "satisfaction" ("the harmony
within a man"), but also the relationship of a person to
the environment ("harmony between a man and his
world") [5]. Such an approach has obvious relevance in
the assessment of quality of life in patients with chronic
medical illnesses (such as congestive heart failure).
Although quality of life research has its roots in the social
sciences, it will be fully accepted by health care practition-
ers only when it answers questions directly related to clin-
ical programs and therapeutic choices. To answer these
and similar questions, future research should be used to
demonstrate the links among medical interventions, clin-
ical and physiologic changes, and quality of life [4,36].
Those involved in psychosomatic research can benefit by
knowledge and familiarity with quality of life measures;
their use and adaptation to psychosomatic research mayClinical Practice and Epidemiology in Mental Health 2005, 1:19 http://www.cpementalhealth.com/content/1/1/19
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help foster greater awareness and comprehension of out-
comes of psychosomatic investigations by colleagues
from other disciplines. Some of the generic health profiles
and cardiac-disease-specific quality of life measures dis-
cussed in this review would likely be most useful along-
side instruments used in psychosomatic investigations of
personality, hostility, depression and social isolation,
which have already been shown to be relevant to patients
with heart disease [11].
The future will show whether quality of life research was a
fashionable and transient movement at the end of the
twentieth century or a serious endeavour with profound
implications for the daily practice of medicine, for out-
come assessment in clinical trials and health services
research, for health needs assessment of populations, and
for resource allocation [5].
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